SCHEMBL6693849

SCHEMBL6693849

NC(=O)[N+]1(Cc2ccc(Oc3ccc(Cl)cc3)cc2)C[C@H](C(=O)O)NC1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR5 Q9H228 1/20 0.44
PPARG P37231 3/20 0.36
PPARA Q07869 3/20 0.36
LTA4H P09960 2/20 0.35
EPHX2 P34913 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.35
DAGLA Q9Y4D2 1/20 0.35
FAAH O00519 1/20 0.34
FFAR1 O14842 1/20 0.34
MMP2 P08253 3/20 0.34
MMP9 P14780 2/20 0.34
MMP1 P03956 1/20 0.34
MMP3 P08254 1/20 0.34
MMP13 P45452 1/20 0.34
EGLN1 Q9GZT9 1/20 0.33
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
KMT2A Q03164 1/20 0.33
CHEK2 O96017 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6693897 0.89 MMP13 (0.43) S1PR5LTA4HEPHX2MMP2MMP9
SCHEMBL6693902 0.88 ACACB (0.34) S1PR5ALDH1A1LMNAFAAHMMP2
SCHEMBL6694975 0.85 MMP2 (0.46) PPARGPPARALMNAMMP2MMP9
SCHEMBL6688866 0.79 MMP1 (0.39) MMP2MMP9MMP1MMP3MMP13
SCHEMBL6698708 0.79 MMP13 (0.48) FAAHMMP2MMP9MMP1MMP3
SCHEMBL6692369 0.79 S1PR5 (0.41) S1PR5FFAR1MMP2MMP9MMP1
SCHEMBL7673139 0.78 MMP13 (0.41) S1PR5PPARGPPARALTA4HEPHX2
SCHEMBL7862190 0.75 S1PR5 (0.37) S1PR5PPARGPPARALTA4HEPHX2
SCHEMBL6690308 0.73 S1PR5 (0.40) S1PR5PPARGPPARALTA4HEPHX2
SCHEMBL6694306 0.67 S1PR5 (0.36) S1PR5PPARGPPARALTA4HEPHX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1134215-B1 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases PFIZER PROD INC (US) 2004-10-06 EP claimed
US-20020147224-A1 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases ROBINSON RALPH P (US) 2002-10-10 US claimed
US-20010041710-A1 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases PFIZER PRODUCTS INC. 2001-11-15 US claimed
EP-1134215-A1 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases Pfizer Products Inc. (US) 2001-09-19 EP claimed
EP-1134215-B1 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases PFIZER PROD INC (US) 2004-10-06 EP disclosed
US-20020147224-A1 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases ROBINSON RALPH P (US) 2002-10-10 US disclosed
US-6458822-B2 (4R)-1-(4-(4-FLUOROPHENOXY)BENZYL)-2-OXO-IMIDAZOLIDINE-4 -CARBOXYLIC ACID HYDROXYAMIDE, FOR EXAMPLE; TREATING VARIOUS DISEASES INCLUDING OSTEOARTHRITIS, RHEUMATOID ARTHRITIS, CANCER, OSTEOPOROSIS, STROKES PFIZER INC. 2002-10-01 US disclosed
US-20010041710-A1 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases PFIZER PRODUCTS INC. 2001-11-15 US disclosed
EP-1134215-A1 2-oxo-imidazolidine-4-carboxylic acid hydroxamine compounds that inhibit matrix metalloproteinases Pfizer Products Inc. (US) 2001-09-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020147224-A1 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases MMP1, MMP8, MMP13 S1PR5 691/4885PPARG 1856/4885PPARA 3044/4885
US-20010041710-A1 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases MMP1, MMP8, MMP13 S1PR5 691/4885PPARG 1856/4885PPARA 3044/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.